EnaVate Sciences is a biopharmaceutical company focused on developing innovative therapies for patients with immunological diseases. The company leverages its proprietary R&D platform to discover and advance mid-to-late-stage clinical development programs.

EnaVate Sciences

Enavate Sciences is a platform dedicated to supporting therapeutic companies advancing medicines and enabling technologies with transformative potential to address patient need. Through the application of capital support and operational experience, Enavate strives to enable and empower a diverse portfolio of therapeutics companies to accelerate innovation. To learn more about Enavate, please visit www.enavatesciences.com. 

Patient Square Capital

Enavate Sciences

Sionna Therapeutics announced this morning that it has raised $182 million in Series C financing led by Enavate Sciences alongside new and existing investors. The funding will help advance the clinical development of a novel small molecule treatment for cystic fibrosis. Enavate’s Edd Fleming will join Sionna Therapeutics’s Board as a part of the transaction. Read the announcement here: https://lnkd.in/gsGC__-7
#therapeutics #healthcare #investing #CysticFibrosis

Health care finance veteran Christine Del Corsano has joined our leadership team as Chief Financial Officer. With fifteen years of recent leadership experience in finance and operations in health care investment banking, Christine will lead finance and operations at Enavate as we advance and execute our strategic plan. Read the announcement here: https://lnkd.in/eHXucqvC  #healthcare #privateequity

ICYMI - Earlier this week, Enavate Sciences supported Graviton Bioscience in its latest financing round. The funding will advance Graviton’s pipeline of drug candidates and ROCK2 therapies to treat a range of fibrotic, inflammatory, and neurologic conditions. Read the full announcement here: https://lnkd.in/e7bdC_yV 

#Therapeutics #Healthcare #Investing  

Enavate Sciences supports Graviton Bioscience in its latest financing round together with Cormorant Asset Management, LP, Pontifax Venture Capital and Ovid Therapeutics. Representing our eighth portfolio investment in partner companies to date, this additional funding will advance Graviton’s pipeline of drug candidates and ROCK2 therapies to treat a range of fibrotic, inflammatory, and neurologic conditions.

Read the announcement here: https://lnkd.in/etXG3Urs 

#therapeutics #healthcare #investing  

Sudo Biosciences has raised $116M in Series B financing, co-led by Enavate Sciences and TPG Life Sciences Innovation. The investment will help advance the development of two new TYK2 inhibitors, with the aim of improving health outcomes for patients with severe autoimmune and neuroinflammatory conditions including multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS). Read the announcement here:  https://lnkd.in/edgkg4dg #therapeutics #healthcare #investing #biopharmaceuticals  

Metric
Company Name	EnaVate Sciences
Symbol
MSH ID	COM:ENAVATESCIENCES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biopharmaceuticals
Country	US
Stage
Employee Count	10
Website	enavatesciences.com
LinkedIn	enavate-sciences
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ENAVATESCIENCES

EnaVate Sciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue